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Abstract We conducted a randomized, double-blind trial
to assess the effect of 28.2 lg teriparatide versus placebo
(1.4 lg teriparatide) on reduction of the incidence of ver-
tebral fractures. Individuals enrolled in this study included
patients with primary osteoporosis with one to five verte-
bral fractures and capable of self-supported walking.
Attention was focused on incident vertebral fractures,
change in bone mineral density (BMD) of the lumbar spine,
and safety. A total of 316 subjects participated in the study,
which lasted up to 131 weeks. Incident vertebral fractures
occurred in 3.3 % of subjects in the 28.2 lg teriparatide-
treated group and 12.6 % of subjects in the placebo group
during the 78-weeks study period. Kaplan–Meier estimates
of risk after 78 weeks were 7.5 and 22.2 % in the teri-
paratide and placebo groups, respectively, with a relative
risk reduction of 66.4 % by teriparatide (P = 0.008).
Lumbar BMD in the 28.2 lg teriparatide group increased
significantly by 4.4 ± 4.7 % at 78 weeks, which was sig-
nificantly higher than the corresponding data in the placebo
group (P = 0.001). Adverse events were observed in
86.7 % of individuals in the teriparatide group and 86.1 %
of those in the placebo group. In conclusion, weekly
injection of a low-dose of teriparatide (28.2 lg) reduced
the risk of incident vertebral fractures and increased lumbar
BMD.
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Introduction
Daily injection of 20 lg teriparatide, an N-terminal frag-
ment of amino acid sequence 1–34 of parathyroid hormone
(PTH), increases bone formation and bone mineral density
(BMD) [1], thereby improving the microarchitecture of
both trabecular and cortical bone [2–5]. Once-weekly
injection of 28.2 lg and 56.5 lg teriparatide has been
shown to increase BMD in patients with osteoporosis by
increasing bone formation [6]. In the 28.3-lg group, only
bone-type alkaline phosphatase increased significantly at
4 weeks. Temporal stimulation of bone formation may
affect an increase of BMD and contribute to fracture risk
reduction. Moreover, injection of 56.5 lg teriparatide once
a week reduced the risk of fracture in patients with primary
osteoporosis, including older postmenopausal women and
men in the Teriparatide Once-Weekly Efficacy Research
(TOWER) trial [7].
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Prior to the TOWER trial, a once-weekly teriparatide
(28.2 lg) trial for reducing fracture risk was stopped early
due to the occurrence of osteosarcoma in rats in a con-
current preclinical trial.
In the present study, we report the effects of a low-dose
of teriparatide (28.2 lg), corresponding to one-half of that
used in the more recently reported once-weekly teriparatide
study [7], for preventing vertebral fractures and increasing
BMD in men and postmenopausal women with
osteoporosis.
Subjects and Methods
This was a randomized, double-blind trial to assess the
effect of 28.2 lg teriparatide versus placebo (1.4 lg teri-
paratide) on reduction of the incidence of vertebral frac-
tures over a period of 3 years. A total of 329 patients were
randomly allocated at 78 sites. Subjects were supplemented
with 400 mg calcium throughout the study period. Men and
postmenopausal women with primary osteoporosis with
one to five vertebral fractures and capable of self-supported
walking were eligible for enrollment. Diagnosis of osteo-
porosis was made according to the criteria of the Japanese
Society for Bone and Mineral Research [8].
Prevalent vertebral fractures at enrollment were subjected
to lateral spine X-ray examination of the thoracic and lumbar
vertebrae, with quantitative assessment according to the
criteria of the Japanese Society for Bone and Mineral
Research [9, 10]. Patients with secondary osteoporosis [8];
hypersensitivity, such as bronchial asthma or rashes;
hypercalcemia; probable pregnancy; primary hypo- or
hyperparathyroidism; past history of drug allergy; severe
complications, such as cardiac, renal, or liver dysfunction;
mental disease; dementia; or severe deformity of the spine
were excluded. Patients who had taken bisphosphonates
within 48 weeks prior to entry in the study and those treated
with calcitonin, active vitamin D derivatives, vitamin K,
raloxifene, sex hormone replacement, or anabolic steroids
within the previous 8 weeks were also excluded. Serum
levels of vitamin D were not measured; therefore, vitamin D
deficiency may have been present in this study.
The protocol, which was carried out in accordance with
the ethical standards established in the 1964 Declaration of
Helsinki and its later amendments, was approved by the
internal human studies review board at each center; and
informed consent was obtained from each patient.
Randomization
Patients who satisfied all of the eligibility criteria were
randomly assigned in a 1:1 ratio to receive 28.2 lg teri-
paratide or placebo (1.4 lg teriparatide). Treatment was
assigned by computerized dynamic allocation, which was
balanced for age, number of prevalent vertebral fractures,
and weight via a central enrollment center. The randomi-
zation sequence was created by the same individual
responsible for investigational product randomization.
Registered subjects visited the clinic every week, and
physicians injected in a blinded fashion 28.2 lg teripara-
tide or placebo.
Procedures
The primary end point was incident vertebral fractures.
Secondary end points were incident fractures other than
vertebra and change of lumbar spine BMD. All investigators
who evaluated the end points were unaware of the study-
group assignments of the subjects. Lateral radiographs of the
thoracic and lumbar spine were taken at baseline and at 26,
52, 78, and 102 weeks later or upon termination of the trial.
One expert investigator independently evaluated the X-ray
pictures of the vertebrae from Th4 to L5. Incident vertebral
fractures were defined quantitatively in cases where the
anterior, posterior, or middle vertebral height had decreased
by 20 % or more from baseline in previously nonfractured
vertebrae [9, 10]. Nonvertebral fracture was defined by each
physician. Dual-energy X-ray absorptiometric (DXA) mea-
surements of the lumbar spine BMD (posteroanterior pro-
jection) were performed at baseline and at 26, 52, 78, and
102 weeks. Lumbar DXA was measured at 37 sites with
QDR (Hologic, Bedford, MA) and DPX (GE Healthcare,
Fairfield, CT) machines in this study. Technicians at each
study site provided quality assurance for the longitudinal
adjustment by calibrating each machine with standardized
phantoms. All DXA measurements were analyzed centrally
by a radiologist (M. F.) who was blinded to treatment-group
assignment.
All subjects were questioned about adverse events (AEs)
at each visit, and all AEs were analyzed regardless of the
investigators’ assessments of causality. Data regarding AEs
and adverse drug-related reactions (ADRs) were coded by
system organ class or preferred terms from Adverse Drug
Reaction Terminology (1996) supervised by Japanese Min-
istry of Health and Welfare. The sponsor (Asahi Kasei
Pharma, Tokyo, Japan) produced the teriparatide, monitored
each study site, collected the data, and ensured quality con-
trol by source data verification during the study period.
Statistical Analysis
All randomized patients who received any dose of a drug
used in the study were included in the safety analysis, and
all randomized patients subjected to drug administration
who finished the baseline assessment and at least one
T. Fujita et al.: Low-Dose Teriparatide and Vertebral Fracture Risk 171
123
postrandomization assessment were included in the effi-
cacy analysis. Analysis of vertebral fracture incidence
included subjects who underwent radiography at baseline
and at least once during the study period. The incidence of
new vertebral fractures was analyzed by a log-rank test
stratified by the number of prevalent vertebral fractures at
baseline. Kaplan–Meier estimates of new vertebral fracture
incidence were calculated each time radiography was
performed. Reported P values were defined by a two-sided
alpha of 0.05.
Two-sided Student’s t tests were used to determine the
intergroup differences in changes in BMD. The incidence
of AEs and ADRs were compared by Fisher’s exact test.
Results from spinal radiographs, BMD, and other variables
were collected centrally and transferred for statistical
analyses. The authors had access to all of the data and take
responsibility for the veracity of the analyses.
Results
This study was started in June 1999. A total of 316 subjects
participated in the study (158 in each group), and injections
of the test drugs were stopped in March 2002. Thirty-three
subjects (22.2 %) in the teriparatide group and 22 subjects
(13.9 %) in the placebo group discontinued due to AEs or
subject request. The duration of observation in each group
after completion of injections is summarized in Table 1.
The physician recorded the number of injections as a
measure of compliance. The longest observation period
was 131 weeks in the placebo group (n = 1). The mean
length of the observation period was 47.4 weeks in the
teriparatide group and 50.8 weeks in the placebo group,
with no significant difference between the two groups
(P = 0.399). Eight subjects in the teriparatide group and
15 in the placebo group were excluded from this analysis
because of a lack of data for evaluation, discontinuation of
previous treatment before obtaining informed consent, or
low BMD associated with nonosteoporotic diseases such as
multiple myeloma.
There were no statistically significant differences in
baseline characteristics between the 28.2 lg teriparatide
and the placebo group (Table 2). Incident vertebral frac-
tures occurred in 3.3 % of subjects in the 28.2 lg teri-
paratide group and 12.6 % in the placebo group during the
78-weeks observation period. Kaplan–Meier estimates of
risk after 78 weeks were 7.5 % [95 % confidence interval
(CI) 0.3–14.7] and 22.2 % (95 % CI 12.4–32.0) in the
teriparatide and placebo groups, respectively, with a rela-
tive risk reduction (RRR) of 66.4 % by teriparatide
(P = 0.008; Fig. 1). Significant reductions in vertebral
fracture risk were also observed between the two groups
during the first 26 and 52 weeks (Fig. 2).
There was no significant difference in the incidence of
total nonvertebral fractures at 78 weeks between the teri-
paratide and placebo groups (3.3 and 5.6 %, respectively;
RRR = 49.3 %). Lumbar BMD in the 28.2 lg teriparatide
group increased by 3.1 ± 4.5 % at 26 weeks, 4.7 ± 4.9 %
at 52 weeks, and 4.4 ± 4.7 % at 78 weeks, which were
significantly higher than the corresponding values in the
placebo group (P \ 0.05) (Fig. 3).
Safety data were collected in all of the 316 randomized
cases. AEs were observed in 86.7 % of subjects in the
teriparatide group and 86.1 % in the placebo group
(P = 1.000), with no significant differences between the
two groups. The incidence of ADRs coded by system organ
class in the two groups during the observation period is
listed in Table 3. The total rate of ADRs in the teriparatide
group was significantly higher than that in the placebo
group (24.1 and 9.5 %, respectively; P = 0.001). The
major ADRs (n C 5) in the teriparatide group were nausea
(nine cases, 5.7 %) and vomiting (six cases, 3.8 %).




Teriparatide group Placebo group P*
n % n %
B26 52 32.9 52 32.9 0.625
27–52 44 27.8 33 20.9
53–78 27 17.1 34 21.5
79–104 24 15.2 26 16.5
[104 11 7.0 13 8.2
The maximum observation period was 131 weeks in the placebo
group (n = 1)
* P values were calculated by v2 test
Table 2 Baseline characteristics
Item Teriparatide group Placebo group P*
(n = 150) (n = 143)
Age (years) 71.6 ± 6.7 71.3 ± 6.9 0.911
Female, cases (%) 144, 92.3 % 134, 93.7 % 0.532
Height (cm) 148.3 ± 6.6 149.4 ± 6.5 0.138
Weight (kg) 50.5 ± 8.1 49.8 ± 7.7 0.452
BMI (kg/m2) 23.0 ± 3.2 22.4 ± 3.3 0.093
Lumbar BMD T score -2.80 ± 1.10 -3.02 ± 0.88 0.180
Prevalent vertebral fracture, cases (%)
1 59, 39.3 % 55, 38.5 % 0.526
2 36, 24.0 % 49, 34.3 %
3 55, 36.7 % 39, 27.3 %
Values are mean ± SD or n, %
BMI body mass index, BMD bone mineral density
* P values were calculated by t test for continuous variables and Chi
squared test for binary variables
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Discussion
In the present study, a significant reduction in the risk of
vertebral fracture was observed in the weekly 28.2 lg
teriparatide-treatment group compared to the placebo
group, with an RRR of 68.4 % over the 78-weeks period.
Furthermore, BMD increased significantly to 4.4 % in the
teriparatide but not the placebo group. However, the two
main effects of weekly 28.2 lg teriparatide in this study
were less impressive than those observed with weekly
56.5 lg teriparatide treatment (RRR = 80, 6.7 %;
TOWER trial) [7]. The difference in the observed effects
on BMD may be explained by the dose of teriparatide.
Based on our findings of the differential effects of weekly
treatment with 28.2 lg (100 U) and 56.5 lg (200 U) teri-
paratide on BMD in our previous dose-finding study [6],
the 3.6 % increase with 28.2 lg teriparatide in the dose-
finding study is comparable to the value obtained in this
study. Thus, the difference in BMD increase appears to
parallel the antifracture effect.
A simple dose-response relationship alone, however, is
insufficient to explain the remarkable effect of a lower dose
of teriparatide given weekly in comparison to the effects
observed with a higher daily dose [6]. In experimental
studies where teriparatide caused simple augmentation of
bone formation by osteoblasts via the Wnt pathway [11–
14], IGF-I system [15–17], and others, a higher total dose
resulted in a proportionally higher response. Therefore,
continuous administration providing a higher total dose
should theoretically result in a greater response than
intermittent administration that inevitably restricts the total
dose. However, daily and weekly teriparatide regimens
may work by different mechanisms of action. Further
prospective studies directly comparing the two dose regi-
mens may clarify this issue.
The actions of teriparatide and intact PTH(1–84) are
quite similar but not identical [18]. Upon teriparatide
administration, a rather complex relationship exists
between the administered teriparatide and secreted
endogenous PTH(1–84) whereby teriparatide inhibits the
secretion of PTH(1–84) in vivo [19–21] and its release
from bovine parathyroid gland in vitro [22]. By recogniz-
ing the cumulative actions of PTH and its fragments and
taking into consideration the combined effects of the direct
action of teriparatide itself and changes to endogenous
PTH(1–84), it may be possible to elucidate the yet
unknown action of PTH in osteoporosis, thereby facilitat-
ing the development of an ideal dosing schedule for teri-
paratide administration. Shiraki et al. [21] indicated that a
single injection of 28.2 or 56.5 lg of teriparatide reduces
the level of endogenous PTH(1–84). Suppression of
Fig. 1 Incidence of new vertebral fractures during the study period
(Kaplan–Meier method). Solid line teriparatide group, dashed line




Fig. 2 Incidence of new vertebral fractures assessed every 26 weeks.
Black box teriparatide group, gray box placebo group, RRR relative
risk reduction
P < 0.001
P < 0.001 P < 0.001
P = 0.001 P < 0.001
P = 0.007
Fig. 3 Mean and standard deviation of changes in lumbar bone
mineral density over 78 weeks. P \ 0.05 versus baseline using a
paired t test and versus the placebo group using an unpaired t test
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endogenous PTH appears to be greater in the 56.5 lg ter-
iparatide group than in the 28.2 lg group, which is parallel
to the effects on BMD and fracture prevention. In addition,
excessive levels of endogenous PTH are not necessarily a
part of the osteoporosis phenotype but have often been
observed in postmenopausal osteoporosis [23] due to
vitamin D deficiency, renal insufficiency, or other causes of
secondary hyperparathyroidism. Effective suppression of
endogenous PTH(1–84) may therefore be one of the factors
reducing bone resorption and preventing fracture. Ade-
quate suppression of endogenous PTH(1–84) by teripara-
tide may be particularly important in severely osteoporotic
patients who are frequently in a state of secondary
hyperparathyroidism.
The incidence rate of ADRs was 24.1 % in this study,
which is similar to that observed with a 28.2 lg dose in our
previous dose-finding study (19 %) [6]. This rate is lower,
however, when compared to the rate observed with a
56.5 lg (200 U) dose (42 %). The incidence of ADRs may
also be affected by the dose of teriparatide.
The first limitation of this study is the unexpected and
premature discontinuation of the originally planned trial
due to osteosarcoma observed in rats in a concurrent pre-
clinical study. The total number of subjects who were
enrolled in the trial, however, was over 140 in each group;
and the observation period was not different between the
two groups. Moreover, the BMD results in this study
confirmed those of our previous dose-finding study [6].
Therefore, it appears reasonable to expect wide and sig-
nificant implications of the use of low-dose once-weekly
teriparatide for increasing BMD. Another limitation is that
serum 25-hydroxyvitamin D was not measured; therefore,
subjects with secondary osteoporosis due to low levels of
vitamin D may have been included in this study. However,
measurements of serum Ca, P, and alkaline phosphatase
were considered to be adequate for excluding patients with
vitamin D deficiency and osteomalacia.
In conclusion, a lower weekly dose of teriparatide
(28.2 lg) reduced the risk of incident vertebral fractures
and increased lumbar BMD.
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